Kinase inhibitors are a highly successful class of novel targeted treatments which have revolutionised cancer treatment over the past fifteen years. Kinase inhibitors have been shown to have lower attrition rates in the clinical versus other modalities.

Inflection’s pipeline of kinase inhibitors were licensed from the Spanish National Cancer Research Centre (CNIO) following an extensive global in-licensing process. The CNIO has a global reputation for excellence in cancer research and has its own drug discovery program.


The pipeline comprises  IBL-202, a first-in-class dual PIM and PI3K inhibitor with potential in B-cell malignancies, AML and multiple myeloma.  The IBL-100 series, comprises highly selective pan-PIM inhibitors currently in preclinical stages of development.

The partnered pipeline comprised AUM302 (formerly IBL-302), partnered with AUM Biosciences.  


Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade